A proposal for a new classification of T4 breast cancer as stage IIIC: a report from the Korean Breast Cancer Society

被引:0
作者
Hee Jeong Kim
Hwa Jung Kim
Sae Byul Lee
Hyeong-Gon Moon
Woo Chul Noh
Young Up Cho
Youngbum Yoo
Sei Hyun Ahn
机构
[1] University of Ulsan,Division of Breast and Endocrine, Department of Surgery, College of Medicine, Asan Medical Center
[2] University of Ulsan,Department of Preventive Medicine, College of Medicine, Asan Medical Center
[3] Seoul National University College of Medicine,Department of Surgery and Cancer Research Institute
[4] Korea Institute of Radiological and Medical Sciences,Department of Surgery, Korea Cancer Center Hospital
[5] Inha University Hospital,Department of Surgery, Inha University College of Medicine
[6] School of Medicine Konkuk University,Konkuk University Medical Center
来源
Breast Cancer Research and Treatment | 2015年 / 153卷
关键词
AJCC classification; Stage IIIB; Stage IIIC; Inflammatory breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study is to investigate staging system of the stage IIIB and stage IIIC Breast cancer and determine the criteria for an update of the classification system. Since AJCC 6th edition, it is pointed out that stage IIIB showed a worse outcome compared with stage IIIC. Using information from two databases, including the nationwide Korean Breast Cancer Registry (KBCR), three cohorts composed of patients from the asan medical center from 1989 to 2002 (cohort I), from 2003 to 2008 (cohort II), and KBCR from 2003 to 2005 (cohort III) were assembled. New classifications were suggested that rearranged stage IIIB as T1-3N3 disease and stage IIIC as T4 any N disease. From the joint analysis of 9640, invasive breast cancer patients from cohorts I and II showed the stage IIIB group showed a significantly worse DFS (HR 10.4, 95 % CI 6.9–15.7) compared with the stage IIIC group (HR 7.2, 95 % CI 5.9–8.7). T4d breast cancer showed worse DFS than T4 abc breast cancer but not significant (p = 0.505). The survival of patients with T1N3 and T2N3 tumors was higher than the other groups, and patients with T4N3 tumors showed the worst survival outcomes in terms of DFS, CSS. Using new suggested classification, in cohort III, the stage IIIB HR for CSS was changed from 15.4 (95 % CI 10.6–22.1) in the AJCC 6th edition to 12.6 (95 % CI 10.1–15.6) in the proposed new staging system. The stage IIIC HR for CSS was changed from 13.3 (95 % CI 10.7–16.4) in the AJCC 6th edition to 18.9 (95 % CI 14.0–25.6) in the proposed new staging using stage I as a reference. Reclassification of T4 any N disease as stage IIIC and T1-3N3 disease as stage IIIB is appropriate.
引用
收藏
页码:153 / 160
页数:7
相关论文
共 85 条
[1]  
Diab SG(1998)Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy J Clin Oncol 16 1655-1660
[2]  
Hilsenbeck SG(1980)Management and survival of female breast cancer: results of a national survey by the American College of Surgeons Cancer 45 2917-2924
[3]  
de Moor C(1998)erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1361-1370
[4]  
Clark GM(2005)Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes Cancer 104 700-707
[5]  
Osborne CK(2007)Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society J Clin Oncol 25 2360-2368
[6]  
Ravdin PM(2010)Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society J Clin Oncol 28 1692-1699
[7]  
Elledge RM(2014)The basic facts of Korean breast cancer in 2011: results of a nationwide survey and breast cancer registry database J Breast Cancer. Korean Breast Cancer Soc. 17 99-106
[8]  
Nemoto T(2003)Changes in the 2003 American Joint Committee on cancer staging for breast cancer dramatically affect stage-specific survival J Clin Oncol 21 3244-3248
[9]  
Vana J(2004)Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy J Clin Oncol 22 4067-4074
[10]  
Bedwani RN(2014)Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg 219 534-544